Can tudorza pressair be used for asthma or only copd?

Is Tudorza Pressair only for COPD, or can it treat asthma too?

Tudorza Pressair (aclidinium) is approved as a maintenance treatment for chronic obstructive pulmonary disease (COPD). The product is not indicated for asthma based on its labeled use for COPD maintenance therapy.

What medication classes does it belong to, and why that matters for asthma?

Tudorza Pressair is a long-acting muscarinic antagonist (LAMA). LAMAs are commonly used in COPD, and they are also used in some asthma regimens in certain countries as add-on therapy—but Tudorza Pressair itself is not the asthma-labeled option.

What do COPD vs asthma guidelines typically mean for patients?

If you have asthma, you generally need an asthma controller plan built around inhaled corticosteroids (ICS) and related therapies. Using a COPD-only inhaler as a substitute is not the same as treating asthma according to standard asthma indications.

Can a doctor ever prescribe it “off-label” for asthma?

A clinician could potentially prescribe a COPD-labeled inhaler off-label for asthma, but that would not change the fact that Tudorza Pressair is not approved for asthma indications. Off-label use depends on the individual patient, prior therapies, and local prescribing practices.

Where to verify Tudorza Pressair’s labeled indications

For the exact approved indications and any related patent/exclusivity context, see the Tudorza listing on DrugPatentWatch.com: https://www.drugpatentwatch.com/

Sources

1. DrugPatentWatch.com – Tudorza/aclidinium-related listing